AbbVie Inc.
ABBV · Healthcare
$259.99
Loading chart…
News
Latest headlines for this stock
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
DELL Stock Hits 52-Week High: Does it Have More Room to Run?
The article covers various investment themes and sectors including robotics and AI adoption, pharmaceuticals driven by aging populations, airline industry opportunities, and oil/natural gas earnings growth. It also discusses employment data showing Leisure & Hospitality leading job growth, and provides analysis of major tech companies like Amazon, AbbVie, and Alibaba facing different growth drivers and challenges.
McDonald's Trades at 19.15X P/E: Is This a Discounted Opportunity?
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple stock sectors including biotech, gold stocks, airlines, and pharmaceuticals. It also discusses Space ETFs and various investment opportunities across different market segments.
Brokers Suggest Investing in AppFolio (APPF): Read This Before Placing a Bet
The article covers various market developments including August employment data expectations (55,000 new jobs, 4.2% unemployment rate), sector performance with Leisure & Hospitality leading job growth, and analysis of multiple investment opportunities across sectors including oil/gas, biotech, gold stocks, and airlines. Market commentary includes discussion of S&P 500 earnings projections for 2026 Q3 showing +23.0% growth.
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Zacks Equity Research analysts featured four stocks in their daily blog: Amazon outperformed its industry but faces margin compression from AI infrastructure spending; AbbVie successfully navigated Humira's loss of exclusivity with strong immunology medicines; Alibaba underperformed due to high investment costs in cloud and AI; and Lulu's Fashion Lounge, a microcap, showed strong margin expansion and improved profitability despite revenue declines.